Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond.
Alzheimer's disease (AD) is the most prevalent form of dementia in the elderly population worldwide. Despite the major unmet clinical need, no new medications for the treatment of AD have been approved since 2003. Galantamine is an acetylcholinesterase inhibitor that is also a positive allosteric modulator at the α4β2 and α7nACh receptors. Memantine is an N-methyl-d-aspartate receptor modulator/agonist. Both galantamine and memantine are FDA-approved medications for the treatment of AD. The objective of this review is to highlight the potential of the galantamine-memantine combination to conduct randomized controlled trials (RCTs) in AD. Several studies have shown the combination to be effective. Neurodegenerative diseases involve multiple pathologies; therefore, combination treatment appears to be a rational approach. Although underutilized, the galantamine-memantine combination is the standard of care in the treatment of AD. Positive RCTs with the combination with concurrent improvement in symptoms and biomarkers may lead to FDA approval, which may lead to greater utilization of this combination in clinical practice.
['Koola|Maju Mathew|MM|']
D000544:Alzheimer Disease D002800:Cholinesterase Inhibitors D004359:Drug Therapy, Combination D018691:Excitatory Amino Acid Antagonists D005702:Galantamine D006801:Humans D008559:Memantine D018697:Nootropic Agents D016032:Randomized Controlled Trials as Topic D016194:Receptors, N-Methyl-D-Aspartate
Alzheimer's disease Galantamine Memantine Aducanumab KAT II inhibitor Major neurocognitive disorder PET tracers